Seqirus files for European approval for QIVc

28 February 2018

UK-headquartered Seqirus today announced its intention to commercialize its cell-based quadrivalent flu vaccine (QIVc) in Europe.

Seqirus, a subsidiary of Australia’ CSL Limited (ASX: CSL) has submitted a Marketing Authorization Application (MAA) for QIVc to the European Medicines Agency and is preparing for launch in European countries in the 2019-20 influenza season. The company is seeking an initial age indication of four years and above for QIVc and has begun additional clinical studies to ultimately achieve an age indication of six months and above.

The vaccine, which is already available in the USA since its regulatory approval in 2016, will be the first four-strain, cell-culture derived, inactivated season influenza vaccine to become available in Europe if approved by the EMA

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK